Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
Conclusions
Although hepatocellular injury following long-term tolvaptan treatment in ADPKD subjects was infrequent and reversible, the potential for serious irreversible injury exists. Regular monitoring of transaminase levels is warranted in this patient population.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cirrhosis | Clinical Trials | Databases & Libraries | Drugs & Pharmacology | Heart | Heart Failure | Liver | Polycystic Kidney Disease | Study | Urology & Nephrology